Welcome to our dedicated page for IQVIA Holdings news (Ticker: $IQV), a resource for investors and traders seeking the latest updates and insights on IQVIA Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IQVIA Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IQVIA Holdings's position in the market.
IQVIA Holdings Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $3,737 million, GAAP Net Income of $288 million, and Adjusted EBITDA of $862 million. The company's First-Quarter 2024 Operating Results showed revenue growth of 2.3% on a reported basis and 2.9% at constant currency. R&D Solutions revenue increased by 3.4%, Technology & Analytics Solutions revenue grew by 0.6%, and Contract Sales & Medical Solutions revenue rose by 3.8%. The company's contracted backlog reached $30.1 billion, up 7.9% year-over-year. IQVIA reaffirmed its full-year guidance for 2024, expecting revenue growth of 2.3% to 3.9% and Adjusted Diluted EPS growth of 7.4% to 10.3% year-over-year.
